2024

• 04 Herpes zoster (EuHZV) phase 1 clinical trial approved
• 04 Euvicol-S WHO-PQ approved
• 04 EUPOP Life sciences Boston office opened
• 01 Respiratory syncytial virus vaccine (EuRSV) phase 1 clinical trial IND approved

2023

• 12 Euvicol-S product approval approved
• 11 Currently selected as a world-class product (certified by the Ministry of Trade, Industry and Energy)
• 09 Euvichol® (OCV) overseas finished production technology transfer agreement
• 09 Meningococcal quadrivalent vaccine (EuMCV) overseas technology transfer agreement
• 06 Announcement of interim results of phase 3 clinical trial of Covid-19 vaccine (EuCorVac-19)
• 02 Meningococcal pentavalent vaccine (EuNmCV-5) phase 1 clinical trial IND approved

2022

• 01 Phase 3 clinical trial IND approval for COVID-19 vaccine (EuCorVac-19)

2021

• 11 Typhoid fever vaccine (EuTCV) clinical trial phase 2/3 completed in the Philippines
• 10 Botulinum toxin (ATGC-100) phase 3 clinical trial completed
• 01 COVID-19 vaccine (EuCorVac-19) phase 1/2 clinical trial IND approval

2020

• 10Established a joint venture company, EUPOP Life Sciences, with POP Biotechnologies, Inc. of USA

2019

• 12Received 20 Million Dollar Export Tower Award
• 04Completed construction of Plant 2 (V Plant) in Chuncheon, Korea

2018

• 12Received 10 Million Dollar Export Tower Award
• 03Started construction of Plant 2 (V Plant) in Chuncheon, Korea

2017

• 12Entered into the EcML Technology Transfer Agreement with KIST
• 08Received WHO Prequalification certificate for OCV (Euvichol-Plus)
• 01Listed on KOSDAQ

2016

• 10Started exporting OCV (Euvichol^®) (including one million doses to Haiti, etc.)
• 06Entered into the Long-Term Agreement with UNICEF for OCV (Euvichol^®) supply

2015

• 12Received WHO PQ certification for OCV (Euvichol^®)
• 01Received export license for OCV (Euvichol^®) from KMFDS

2014

• 09Expanded production facilities for Active Pharmaceutical Ingredient for Euvichol^® (w.v.600L)
• 08Completed Phase 3 Clinical Trial for OCV (Euvichol^®) in Philippines
• 08Received investment from Global Health Investment Fund (GHIF) of the Bill and Melinda Gates Foundation

2013

• 12Received IND approval for Phase 3 Clinical Trial of OCV (Euvichol^®) in Philippines

2012

• 07IND approved for Phase 1 Clinical Trial of OCV (Euvichol^®) in Korea
• 06Conducted Government Assignment for next generation typhoid vaccine (Small and Medium Business Administration)
• 03Merged with EuBiopharm Co., Ltd.
• 02Received the Venture Company Certificate

2010

• 12Performed the Technology Transfer and Feasibility study
• 09Entered into the Technology Transfer Agreement for oral cholera vaccine (OCV) with International Vaccine Institute (IVI)
• 03EuBiologics Co., Ltd. founded